Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PDE2A | O00408 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8916786 | 1.00 | TSHR (0.40) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL4820465 | 0.94 | PDE2A (0.39) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL8916197 | 0.94 | PDE2A (0.39) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL7488259 | 0.89 | ALDH1A1 (0.37) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL4816609 | 0.89 | ALDH1A1 (0.37) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL7490417 | 0.89 | ALDH1A1 (0.37) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL4817364 | 0.89 | TSHR (0.38) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL8912330 | 0.88 | TSHR (0.41) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL974960 | 0.88 | LMNA (0.36) | TSHRNPSR1GLASMN1; SMN2LMNA | |
| SCHEMBL4819802 | 0.88 | LMNA (0.36) | TSHRNPSR1GLASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307200-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| WO-2002002563-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH (US) | 2002-01-10 | — | — | WO | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1307200-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
| WO-2002002563-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | TSHR 2567/4885NPSR1 4247/4885GLA 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.